These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 29340082)

  • 21. The trans-membrane domain of Bcl-2α, but not its hydrophobic cleft, is a critical determinant for efficient IP3 receptor inhibition.
    Ivanova H; Ritaine A; Wagner L; Luyten T; Shapovalov G; Welkenhuyzen K; Seitaj B; Monaco G; De Smedt H; Prevarskaya N; Yule DI; Parys JB; Bultynck G
    Oncotarget; 2016 Aug; 7(34):55704-55720. PubMed ID: 27494888
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Venetoclax Synergizes with Radiotherapy for Treatment of B-cell Lymphomas.
    O'Steen S; Green DJ; Gopal AK; Orozco JJ; Kenoyer AL; Lin Y; Wilbur DS; Hamlin DK; Fisher DR; Hylarides MD; Gooley TA; Waltman A; Till BG; Press OW
    Cancer Res; 2017 Jul; 77(14):3885-3893. PubMed ID: 28566329
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dexamethasone treatment promotes Bcl-2 dependence in multiple myeloma resulting in sensitivity to venetoclax.
    Matulis SM; Gupta VA; Nooka AK; Hollen HV; Kaufman JL; Lonial S; Boise LH
    Leukemia; 2016 May; 30(5):1086-93. PubMed ID: 26707935
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting ERK1/2-bim signaling cascades by BH3-mimetic ABT-737 as an alternative therapeutic strategy for oral cancer.
    Shin JA; Kim LH; Lee SJ; Jeong JH; Jung JY; Lee HN; Hong IS; Cho SD
    Oncotarget; 2015 Nov; 6(34):35667-83. PubMed ID: 26447615
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recent advances in canonical versus non-canonical Ca
    Cauwelier C; de Ridder I; Bultynck G
    Biochim Biophys Acta Mol Cell Res; 2024 Jun; 1871(5):119713. PubMed ID: 38521468
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The type 2 inositol 1,4,5-trisphosphate receptor, emerging functions for an intriguing Ca²⁺-release channel.
    Vervloessem T; Yule DI; Bultynck G; Parys JB
    Biochim Biophys Acta; 2015 Sep; 1853(9):1992-2005. PubMed ID: 25499268
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fatty acid synthase (FASN) regulates the mitochondrial priming of cancer cells.
    Schroeder B; Vander Steen T; Espinoza I; Venkatapoorna CMK; Hu Z; Silva FM; Regan K; Cuyàs E; Meng XW; Verdura S; Arbusà A; Schneider PA; Flatten KS; Kemble G; Montero J; Kaufmann SH; Menendez JA; Lupu R
    Cell Death Dis; 2021 Oct; 12(11):977. PubMed ID: 34675185
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preferential targeting of MCL-1 by a hydrocarbon-stapled BIM BH3 peptide.
    Hadji A; Schmitt GK; Schnorenberg MR; Roach L; Hickey CM; Leak LB; Tirrell MV; LaBelle JL
    Oncotarget; 2019 Oct; 10(58):6219-6233. PubMed ID: 31692812
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The BH4 domain of Bcl-2 orthologues from different classes of vertebrates can act as an evolutionary conserved inhibitor of IP
    Ivanova H; Luyten T; Decrock E; Vervliet T; Leybaert L; Parys JB; Bultynck G
    Cell Calcium; 2017 Mar; 62():41-46. PubMed ID: 28179071
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Creating a New Cancer Therapeutic Agent by Targeting the Interaction between Bcl-2 and IP
    Distelhorst CW; Bootman MD
    Cold Spring Harb Perspect Biol; 2019 Sep; 11(9):. PubMed ID: 31110129
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hypomethylating agent decitabine sensitizes diffuse large B-cell lymphoma to venetoclax.
    Zhu F; Crombie JL; Ni W; Hoang NM; Garg S; Hackett L; Chong SJF; Collins MC; Rui L; Griffin J; Davids MS
    Haematologica; 2024 Jan; 109(1):186-199. PubMed ID: 37534528
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Apoptotic Blocks in Primary Non-Hodgkin B Cell Lymphomas Identified by BH3 Profiling.
    Rys RN; Wever CM; Geoffrion D; Goncalves C; Ghassemian A; Brailovski E; Ryan J; Stoica L; Hébert J; Petrogiannis-Haliotis T; Dmitrienko S; Frenkiel S; Staiger A; Ott G; Steidl C; Scott DW; Sesques P; Del Rincon S; Mann KK; Letai A; Johnson NA
    Cancers (Basel); 2021 Feb; 13(5):. PubMed ID: 33670870
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Proapoptotic BH3-only BCL-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrion.
    Deng J; Shimamura T; Perera S; Carlson NE; Cai D; Shapiro GI; Wong KK; Letai A
    Cancer Res; 2007 Dec; 67(24):11867-75. PubMed ID: 18089817
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alpha-helical destabilization of the Bcl-2-BH4-domain peptide abolishes its ability to inhibit the IP3 receptor.
    Monaco G; Decrock E; Nuyts K; Wagner LE; Luyten T; Strelkov SV; Missiaen L; De Borggraeve WM; Leybaert L; Yule DI; De Smedt H; Parys JB; Bultynck G
    PLoS One; 2013; 8(8):e73386. PubMed ID: 24137498
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models.
    Lehmann C; Friess T; Birzele F; Kiialainen A; Dangl M
    J Hematol Oncol; 2016 Jun; 9(1):50. PubMed ID: 27353420
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structure-function analysis of Bcl-2 family proteins. Regulators of programmed cell death.
    Reed JC; Zha H; Aime-Sempe C; Takayama S; Wang HG
    Adv Exp Med Biol; 1996; 406():99-112. PubMed ID: 8910675
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Small-molecule inhibitors of Bcl-2 family proteins are able to induce tumor regression in a mouse model of pre-B-cell acute lymphocytic lymphoma.
    Turner BC; Eves T; Refaeli Y
    DNA Cell Biol; 2008 Mar; 27(3):133-42. PubMed ID: 18163880
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-apoptotic Bcl-XL protein in complex with BH3 peptides of pro-apoptotic Bak, Bad, and Bim proteins: comparative molecular dynamics simulations.
    Lama D; Sankararamakrishnan R
    Proteins; 2008 Nov; 73(2):492-514. PubMed ID: 18452209
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identifying Targetable Vulnerabilities to Circumvent or Overcome Venetoclax Resistance in Diffuse Large B-Cell Lymphoma.
    Adams CM; McBride A; Michener P; Shkundina I; Mitra R; An HH; Porcu P; Eischen CM
    Cancers (Basel); 2024 Jun; 16(11):. PubMed ID: 38893249
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bcl-2 binds to and inhibits ryanodine receptors.
    Vervliet T; Decrock E; Molgó J; Sorrentino V; Missiaen L; Leybaert L; De Smedt H; Kasri NN; Parys JB; Bultynck G
    J Cell Sci; 2014 Jun; 127(Pt 12):2782-92. PubMed ID: 24762814
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.